Genmab A/S (GMAB)
Nasdaq · Healthcare · Biotechnology
$38.48+10.73%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $24.0B
- P/E (trailing)
- 27.5
- Forward P/E
- 25.1
- 52-week range
- $23.62 – $40.17
- 52-week change
- +6.46%
- EPS (trailing)
- $1.40
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors.
Headquarters: Copenhagen, Denmark · 3,119 employees · genmab.com